Abstract
The evolution of the SARS-CoV-2 pandemic continuously produces new variants, which warrant timely epidemiological characterisation. Here we use the dense genomic surveillance generated by the COVID-19 Genomics UK Consortium to reconstruct the dynamics of 71 different lineages in each of 315 English local authorities between September 2020 and June 2021. This analysis reveals a series of sub-epidemics that peaked in the early autumn of 2020, followed by a jump in transmissibility of the B.1.1.7/Alpha lineage. Alpha grew when other lineages declined during the second national lockdown and regionally tiered restrictions between November and December 2020. A third more stringent national lockdown suppressed Alpha and eliminated nearly all other lineages in early 2021. However, a series of variants (mostly containing the spike E484K mutation) defied these trends and persisted at moderately increasing proportions. Accounting for sustained introductions, however, indicates that their transmissibility is unlikely to have exceeded that of Alpha. Finally, B.1.617.2/Delta was repeatedly introduced to England and grew rapidly in the early summer of 2021, constituting approximately 98% of sampled SARS-CoV-2 genomes on June 26.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. We would like to thank our colleagues at EMBL-EBI, the Wellcome Sanger Institute and from COG-UK for stimulating discussions and helpful comments on this manuscript. HSV and MG are supported by a grant from the Department of Health and Social Care. AWJ, EB and MG are beneficiaries from grant NNF17OC0027594 from the Novo Nordisk Foundation. TS is supported by grant 210918/Z/18/Z, and JH and SF by grant 210758/Z/18/Z from the Wellcome Trust. HSV, NDM, AWJ, NG, EB and MG are supported by EMBL.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was done as part of surveillance for COVID-19 under the auspices of Section 251 of the National Health Service Act 2006. It therefore did not require individual patient consent or ethical approval. The COVID-19 Genomics UK (COG-UK) study protocol was approved by the Public Health England Research Ethics Governance Group.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵8 https://www.sanger.ac.uk/project/wellcome-sanger-institute-covid-19-surveillance-team/
↵9 Full list of consortium names and affiliations are in the Appendix
The manuscript was updated to cover the entire sweep of the Delta variant in England (the analysis was extended until June 26, 2021). Further changes include a quantitative assessment of the quality of fit (new Extended Data Figure 3), comparison to a Bayesian phylogeographic analysis (new Extended Data Figure 8d) and also a more systematic selection of LTLAs shown in the main Figures and a new Supplementary Note showing the fits of all LTLAs.
Data Availability
PCR test data are publicly available at https://coronavirus.data.gov.uk/. SARS-CoV-2 genome data and geolocations can be obtained under controlled access from https://www.cogconsortium.uk/data/. A filtered, privacy conserving version of the data set is publicly available at https://covid19.sanger.ac.uk/downloads. The data and a version of the analysis with fewer lineages can be interactively explored at https://covid19.sanger.ac.uk.
https://coronavirus.data.gov.uk/
https://www.cogconsortium.uk/data/
